HB920

Requires drug manufacturers to limit pricing of GLP-1 medications for health insurance plans (OR INCREASE GF EX See Note)

Introduced·2/27/26
Ment Text

Louisiana HB920 mandates drug manufacturers to limit the cost of GLP-1 medications for health insurance plans.

Louisiana HB920 requires drug manufacturers to limit the pricing of GLP-1 medications for health insurance plans, ensuring that insured individuals do not pay more than $200 for a 30-day supply. The bill extends GLP-1 medication coverage to Medicaid, the Office of Group Benefits, and other health plans, regardless of the insured's medical condition or diagnosis. The Louisiana Department of Health may seek federal Medicaid waivers and state plan amendments to implement these provisions.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Insurance Committee
Next
Committee decision

Sponsors

D
1
0
Democratic CaucusRepublican Caucus

History

Mar 9

House

Read by title, under the rules, referred to the Committee on Insurance.

Feb 27

House

Prefiled.

Feb 27

House

Under the rules, provisionally referred to the Committee on Insurance.